KMUH(N-κ-maleimidoundecanoic acid hydrazide) , CAS No.K638935

  • Molecular Weight:  409.4
Item Number
K638935
Grouped product items
SKUSizeAvailabilityPrice Qty
K638935-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$955.90

KMUH

Basic Description

Storage TempStore at 2-8°C,Desiccated
Shipped InWet ice
Product Description

Product introduction:

KMUH is a long, maleimide-and-hydrazide crosslinker for conjugating sulfhydryls (cysteines) to carbonyls (aldehyde or ketones, such as those formed by oxidation of glycoprotein carbohydrates).

Features of KMUH:

Reactive groups:maleimide andhydrazide
Reactive towards: sulfhydryl groups and carbonyl (aldehyde) groups
• Long (19.0A), sulfhydryl-to-aldehyde crosslinker with simple aliphatic spacer arm (noncleavable)
• Maleimide group reacts with sulfhydryl groups to form stable thioether linkages
• Hydrazide group conjugates to oxidized sugars of glycoproteins and carbohydrates
• Usesodium meta-periodate to oxidize glycosylation (e.g., sialic acid) to reactive aldehyde groups
• Use withEDC to conjugate primary amine of hydrazide group to carboxyl groups

Product References:

Crosslinker Application Guide -- search for recent literature references for this product

Reactive Moiety:Amine,Hydrazide,Maleimide

Crosslinker Type:Heterobifunctional

Form:Solid

Spacer:Medium(10 to 30 Å)

Labeling Method:Chemical Labeling

Spacer Arm Length:19.0 Å

Product Properties

ReactivityCarbohydrate-Sulfhydryl

Names and Identifiers

Molecular Weight 409.4

Certificates

C of A & Other Certificates(BSE/TSE, COO)

Chemical and Physical Properties

SolubilityDMF,DMSO

Related Documents

References

1. Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ.  ()  Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4..  Clin Cancer Res,      [PMID:16778107] [http://pubmed.ncbi.nlm.nih.gov/16778107]
2. Wu G, Barth RF, Yang W, Kawabata S, Zhang L, Green-Church K.  ()  Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates..  Mol Cancer Ther,      [PMID:16432162] [http://pubmed.ncbi.nlm.nih.gov/16432162]

Solution Calculators